Tauklarify (florquinitau F 18)
Cerveau Technologies (Lantheus) (LNTH)
ApprovedAug 13, 2026
Marketer take
A tau PET agent for patients being evaluated for Alzheimer's disease, so memory clinics, neurologists and imaging centers are the audience, and it competes directly with Tauvid.
- Sponsor company
- Cerveau Technologies (Lantheus) (LNTH)
- Indication
- To be used for positron emission tomography of the brain in adults with cognitive impairment who are being evaluated for Alzheimer disease to identify patients with tau neurofibrillary tangle pathology
- Therapeutic area
- Diagnostic imaging, Neurology
- Event
- FDA approval
- Date
- Aug 13, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?